BCL-2 PROTEIN IN INVASIVE DUCTAL BREAST CARCINOMAS

Citation
J. Hurlimann et al., BCL-2 PROTEIN IN INVASIVE DUCTAL BREAST CARCINOMAS, Virchows Archiv, 426(2), 1995, pp. 163-168
Citations number
36
Categorie Soggetti
Pathology
Journal title
ISSN journal
09456317
Volume
426
Issue
2
Year of publication
1995
Pages
163 - 168
Database
ISI
SICI code
0945-6317(1995)426:2<163:BPIIDB>2.0.ZU;2-C
Abstract
The bcl-2 gene encodes a protein which inhibits programmed cell death (apoptosis). This protein was detected by immunohistochemical techniqu es in 48% of invasive ductal carcinomas of the breast. It was present in well-differentiated carcinomas with hormonal receptors, and protein s synthesized under the control of oestrogens: pS2, cathepsin D and ER D5. In contrast, bcl-2(+) carcinomas are less frequently positive for p53 and have a Ki67 score under the mean. bcl-2 protects cells against apoptosis. Accumulation of p53 protein, which is indicative of p53 mu tation, would have the same effect; however, these two proteins seem i nversely related, an inverse correlation observed by others in breast cancer cell lines and in lymphomas. Tumours positive for bcl-2 escape apoptosis and have worse prognosis but this is not what is found; surv ival at 5 years, and particularly the absence of recurrence during the first 5 years after surgery, seem to be associated with bcl-2 positiv ity. The bcl-2 protein seems only to be an important prognostic factor in women over 54 years of age. Moreover, p53-bcl-2(+) tumours have a better response to hormonal therapy than p53-bcl-2- tumours.